Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Charles River will curate for AstraZeneca

by Rick Mullin
February 12, 2018 | A version of this story appeared in Volume 96, Issue 7

Charles River Laboratories has signed an agreement granting it access to AstraZeneca’s high-throughput screening (HTS) and compound management infrastructure. The research services provider will place scientists at AstraZeneca’s Centre for Lead Discovery in Cambridge, England, where they will manage the drug firm’s compound collection and run HTS with access to liquid handling and automated storage systems.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.